mesothelin, CRISPR-Cas9, PD-1, TCR
Showing 1 - 25 of >10,000
Solid Tumor, Adult Trial in Beijing (anti-mesothelin CAR-T cells)
Unknown status
- Solid Tumor, Adult
- anti-mesothelin CAR-T cells
-
Beijing, ChinaBiotherapeutic Department and Hematology Department of Chinese P
Aug 6, 2020
COVID-19 Respiratory Infection Trial (PD-1 and ACE2 Knockout T Cells)
Not yet recruiting
- COVID-19 Respiratory Infection
- PD-1 and ACE2 Knockout T Cells
- (no location specified)
Aug 13, 2021
Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn Trial in Worldwide (CTX001)
Active, not recruiting
- Beta-Thalassemia
- +4 more
- CTX001
-
Stanford, California
- +11 more
Nov 30, 2022
Transfusion Dependent Beta-Thalassaemia Trial in Guangzhou, Shenzhen, Tianjin (ET-01)
Active, not recruiting
- Transfusion Dependent Beta-Thalassaemia
- ET-01
-
Guangzhou, Guangdong, China
- +3 more
May 9, 2022
Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma Trial in Nashville (CTX131)
Recruiting
- Clear Cell Renal Cell Carcinoma
- +4 more
- CTX131
-
Nashville, TennesseeResearch Site 1
Mar 21, 2023
NSCLC, Metastatic Non Small Cell Lung Cancer, Stage IV NSCLC Trial in Duarte, Minneapolis (Fludarabine, Cyclophosphamide, CISH
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- +5 more
- Fludarabine
- +4 more
-
Duarte, California
- +1 more
Dec 7, 2022
B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy Trial (CTX112)
Not yet recruiting
- B-cell Lymphoma
- +7 more
- CTX112
- (no location specified)
Dec 12, 2022
Multiple Myeloma, Melanoma, Synovial Sarcoma Trial in Philadelphia (biological, drug, device)
Terminated
- Multiple Myeloma
- +3 more
- NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1
- +3 more
-
Philadelphia, PennsylvaniaUniversity of Pennsylvania
Oct 9, 2020
T Cell Lymphoma Trial in Australia, Canada, United States (CTX130)
Recruiting
- T Cell Lymphoma
- CTX130
-
Duarte, California
- +9 more
May 16, 2022
Multiple Myeloma Trial in Worldwide (CTX120)
Active, not recruiting
- Multiple Myeloma
- CTX120
-
Chicago, Illinois
- +9 more
Jul 14, 2022
Non-hodgkin Lymphoma,B Cell Trial in Beijing (Autologous CD19-STAR-T cell, Fludarabine, Cyclophosphamide)
Recruiting
- Non-hodgkin Lymphoma,B Cell
- Autologous CD19-STAR-T cell
- +2 more
-
Beijing, Beijing, China
- +1 more
Nov 21, 2022
Viral Keratitis, Blindness Eye, Herpes Simplex Virus Infection Trial in Shanghai (BD111 Adult single group Dose)
Completed
- Viral Keratitis
- +3 more
- BD111 Adult single group Dose
-
Shanghai, Shanghai, ChinaEye & Ent Hospital of Fudan University
Aug 20, 2022
Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8 Trial in Canada,
Active, not recruiting
- Metastatic Pancreatic Adenocarcinoma
- +5 more
- Anetumab Ravtansine
- +5 more
-
Birmingham, Alabama
- +44 more
Feb 2, 2023
Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma Trial (PACE CART19)
Withdrawn
- Acute Lymphoblastic Leukemia
- +2 more
- PACE CART19
- (no location specified)
Mar 9, 2022
B-cell Malignancy, Non-Hodgkin Lymphoma, B-cell Lymphoma Trial in Worldwide (CTX110)
Recruiting
- B-cell Malignancy
- +3 more
- CTX110
-
Los Angeles, California
- +27 more
May 6, 2022
Pancreatic Cancer Trial in Guangzhou (TCR-T therapy)
Recruiting
- Pancreatic Cancer
- TCR-T therapy
-
Guangzhou, Guangdong, ChinaSun Yat-sen Memorial Hospital
Aug 10, 2022
Stem Cells in NF1 Tumors of the Central Nervous System
Suspended
- Neurofibromatosis Type 1
- Tumors of the Central Nervous System
- Collection of Stem Cells
-
Washington, District of ColumbiaChildren's National Medical Center
Mar 8, 2022
Gene Editing as a Therapeutic Approach for Rett Syndrome
Recruiting
- Rett Syndrome
- Gene editing in vitro
-
Siena, ItalyUniversity of Siena
Feb 13, 2023
Thalassemia, Beta, Thalassemia Major Trial in Tianjin (VGB-Ex01)
Not yet recruiting
- Thalassemia, Beta
- Thalassemia Major
- VGB-Ex01
-
Tianjin, Tianjin, ChinaRegenerative Medicine Center
Sep 11, 2023
Mesothelioma, Mesotheliomas Pleural, Mesothelioma, Malignant Trial in Bethesda, Nashville (TC-510, Fludarabine,
Recruiting
- Mesothelioma
- +14 more
- TC-510
- +2 more
-
Nashville, TennesseeSarah Cannon Research Institute
Jul 14, 2022
Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn Trial in Nashville (CTX001)
Recruiting
- Beta-Thalassemia
- +4 more
- CTX001
-
Nashville, Tennessee
- +5 more
Feb 2, 2023
Malignant Epithelial Tumors Trial in Portland (TCR-transduced T cells, CDX-1140, Pembrolizumab)
Not yet recruiting
- Malignant Epithelial Neoplasms
- TCR-transduced T cells
- +2 more
-
Portland, OregonProvidence Portland Medical Center
Apr 22, 2022
Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance Trial in Nashville (CTX001)
Recruiting
- Sickle Cell Disease
- +4 more
- CTX001
-
Philadelphia, Pennsylvania
- +3 more
Jan 24, 2023